Literature DB >> 6781108

A successful program of immunizing Rh-negative male volunteers for anti-D production using frozen/thawed blood.

S J Urbaniak, A E Robertson.   

Abstract

Individually matched (rhesus-D) Rh-positive frozen/thawed red blood cells were used to immunize 28 Rh-negative male volunteers. The immunizing schedule consisted of a single unit (200 ml) of frozen/thawed red blood cells, followed by six monthly booster doses (0.5 to 1.0 ml) after a rest period of six months. A final response rate of 93 percent (26 of 28) was achieved. All responders had produced anti-D before the second booster injection (mean detection time 4.25 months). Retrospective analysis indicated that the final response rate and the level of anti-D response could be predicted as early as seven to eight months from the start of immunization. These findings have practical implications for deciding when to discontinue immunization. The Rh genotype of the immunizing cells did not appear to be an important factor in determining the anti-D response, and with the matching system used, antibodies other than anti-C, D, and/or E were not produced. The use of frozen/thawed red blood cells for immunization has the advantage of permitting optimum matching for undesirable red blood cell antigens and minimizing the risk of transmitting disease to the recipients.

Mesh:

Substances:

Year:  1981        PMID: 6781108     DOI: 10.1046/j.1537-2995.1981.21181127486.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  16 in total

1.  Minor RBC Ab and allo-SCT.

Authors:  G S Booth; E A Gehrie; B N Savani
Journal:  Bone Marrow Transplant       Date:  2013-12-09       Impact factor: 5.483

2.  Platelet transfusion - the art and science of compromise.

Authors:  Joan Cid; Sarah K Harm; Mark H Yazer
Journal:  Transfus Med Hemother       Date:  2013-04-26       Impact factor: 3.747

Review 3.  Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype.

Authors:  S Gerald Sandler; Leonard N Chen; Willy A Flegel
Journal:  Br J Haematol       Date:  2017-05-16       Impact factor: 6.998

4.  Difficulties in Immunohaematology : The Weak D Antigen.

Authors:  H Kumar; D K Mishra; R S Sarkar; M Jaiprakash
Journal:  Med J Armed Forces India       Date:  2011-07-21

5.  Prospective Evaluation of a Transfusion Policy of RhD-Positive Red Blood Cells into DEL Patients in China.

Authors:  Wei Xu; Mei Zhu; Bao-Long Wang; Hong Su; Min Wang
Journal:  Transfus Med Hemother       Date:  2014-12-22       Impact factor: 3.747

Review 6.  The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders.

Authors:  Eric A Gehrie; Christopher A Tormey
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

7.  Enigmatic Weak D antigen: An Experience in a Tertiary Care Hospital of East Delhi.

Authors:  Anshu Gupta; Shabnam Mirza; Sarbjeet Khurana; Roopali Singh; Sujata Chaturvedi; Bharat Singh
Journal:  J Clin Diagn Res       Date:  2016-06-01

8.  Low rate of Rhesus immunization from Rh-incompatible blood transfusions during liver and heart transplant surgery.

Authors:  G Ramsey; L F Hahn; F W Cornell; D J Boczkowski; S Staschak; R Clark; R L Hardesty; B P Griffith; T E Starzl
Journal:  Transplantation       Date:  1989-06       Impact factor: 4.939

9.  Platelet Transfusion Induces Alloimmunization to D and Non-D Rhesus Antigens.

Authors:  Johanna Reckhaus; Markus Jutzi; Stefano Fontana; Vera Ulrike Bacher; Marco Vogt; Michael Daslakis; Behrouz Mansouri Taleghani
Journal:  Transfus Med Hemother       Date:  2018-05-24       Impact factor: 3.747

10.  Unmatched Type O RhD+ Red Blood Cells in Multiple Injured Patients.

Authors:  Sabine Flommersfeld; Carsten Mand; Christian A Kühne; Gregor Bein; Steffen Ruchholtz; Ulrich J Sachs
Journal:  Transfus Med Hemother       Date:  2018-03-07       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.